- Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome2021 | Second Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial2018 | First Faculty of Medicine
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | First Faculty of Medicine
- Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic SyndromesPublication without faculty affiliation
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes2016 | First Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- Research Report University Hospital clinical trial AZA-MDS-003Publication without faculty affiliation
- RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS2022 | Faculty of Science, First Faculty of Medicine